SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced a new collaboration with Stanford University. This partnership aims to advance cell engineering and gene editing through SOHM's ABBIE Technology. The collaboration will involve joint research projects, knowledge-sharing initiatives, and technology development programs.
Dr. David Aguilar, COO of SOHM, expressed excitement about the partnership, stating that it will amplify their impact and foster innovation. Specific projects and initiatives under this collaboration are expected to be unveiled in the coming months. This strategic alliance combines SOHM's innovative prowess with Stanford's expertise to tackle challenges in gene editing development.
SOHM, Inc. (OTC PINK:SHMN), un'azienda farmaceutica e biotecnologica, ha annunciato una nuova collaborazione con l'Università di Stanford. Questo partnership mira a promuovere l'ingegneria cellulare e l'editing genetico attraverso la tecnologia ABBIE di SOHM. La collaborazione includerà progetti di ricerca congiunti, iniziative di condivisione delle conoscenze e programmi di sviluppo tecnologico.
Il Dr. David Aguilar, COO di SOHM, ha espresso entusiasmo per la partnership, affermando che amplificherà il loro impatto e favorirà l'innovazione. Progetti e iniziative specifiche sotto questa collaborazione dovrebbero essere svelati nei prossimi mesi. Questa alleanza strategica combina l'innovativa capacità di SOHM con l'esperienza di Stanford per affrontare le sfide nello sviluppo dell'editing genetico.
SOHM, Inc. (OTC PINK:SHMN), una empresa farmacéutica y biotecnológica, ha anunciado una nueva colaboración con la Universidad de Stanford. Esta asociación tiene como objetivo avanzar en la ingeniería celular y la edición genética a través de la tecnología ABBIE de SOHM. La colaboración involucrará proyectos de investigación conjuntos, iniciativas de intercambio de conocimientos y programas de desarrollo tecnológico.
El Dr. David Aguilar, COO de SOHM, expresó su emoción por la asociación, afirmando que amplificará su impacto y fomentará la innovación. Se espera que se revelen proyectos e iniciativas específicos bajo esta colaboración en los próximos meses. Esta alianza estratégica combina la destreza innovadora de SOHM con la experiencia de Stanford para abordar los desafíos en el desarrollo de la edición genética.
SOHM, Inc. (OTC PINK:SHMN), 제약 및 생명공학 회사가 스탠포드 대학교와의 새로운 협력을 발표했습니다. 이 파트너십은 SOHM의 ABBIE 기술을 통해 세포 공학 및 유전자 편집을 발전시키는 것을 목표로 하고 있습니다. 협력은 공동 연구 프로젝트, 지식 공유 이니셔티브 및 기술 개발 프로그램을 포함할 것입니다.
SOHM의 COO인 David Aguilar 박사는 파트너십에 대한 기대감을 표현하며, 이는 그들의 영향을 증대시키고 혁신을 촉진할 것이라고 밝혔습니다. 이번 협력 아래 구체적인 프로젝트 및 이니셔티브가 다음 몇 달 안에 공개될 예정입니다. 이 전략적 동맹은 SOHM의 혁신적인 능력과 스탠포드의 전문성을 결합하여 유전자 편집 개발의 도전 과제를 해결할 것입니다.
SOHM, Inc. (OTC PINK:SHMN), une entreprise pharmaceutique et biotechnologique, a annoncé une nouvelle collaboration avec l'Université de Stanford. Ce partenariat vise à faire avancer l'ingénierie cellulaire et l'édition génique grâce à la technologie ABBIE de SOHM. La collaboration impliquera des projets de recherche conjoints, des initiatives de partage des connaissances et des programmes de développement technologique.
Le Dr David Aguilar, COO de SOHM, a exprimé son enthousiasme pour le partenariat, affirmant qu'il amplifiait leur impact et favorisait l'innovation. Des projets et initiatives spécifiques dans le cadre de cette collaboration devraient être dévoilés dans les mois à venir. Cette alliance stratégique combine l'innovation de SOHM avec l'expertise de Stanford pour relever les défis du développement de l'édition génique.
SOHM, Inc. (OTC PINK:SHMN), ein Pharma- und Biotechnologieunternehmen, hat eine neue Zusammenarbeit mit der Stanford-Universität angekündigt. Diese Partnerschaft zielt darauf ab, Zelltechnik und Gentechnik durch die ABBIE-Technologie von SOHM voranzutreiben. Die Zusammenarbeit wird gemeinsame Forschungsprojekte, Wissensaustauschinitiativen und Technologieentwicklungsprogramme umfassen.
Dr. David Aguilar, COO von SOHM, äußerte seine Begeisterung über die Partnerschaft und erklärte, dass sie ihre Wirkung verstärken und Innovationen fördern wird. Konkrete Projekte und Initiativen im Rahmen dieser Zusammenarbeit sollen in den kommenden Monaten vorgestellt werden. Diese strategische Allianz kombiniert die innovative Kompetenz von SOHM mit der Expertise von Stanford, um Herausforderungen in der Entwicklung der Gentechnik zu bewältigen.
- Partnership with prestigious Stanford University may enhance SOHM's research capabilities
- Collaboration focuses on advancing cell engineering and gene editing technologies
- Potential for accelerated innovation and development in biotechnology sector
- None.
CHINO HILLS, CA / ACCESSWIRE / July 25, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnologycompany that manufactures and markets generic drugs covering numerous treatment categories, announced that it has signed a new agreement with Standford University.
In an exciting development, SOHM announces a groundbreaking collaboration of ABBIE Technology with Stanford University, one of the world's leading research institutions. This strategic partnership aims to bring together the innovative prowess of SOHM Inc. with the cutting-edge expertise of Stanford University to drive forward advancements in cell engineering and gene editing, Dr. David Aguilar, COO, said.
Further, Dr. Aguilar added that the collaboration would encompass joint research projects, knowledge-sharing initiatives, and technology development programs. By combining the resources and talent from both entities, they seek to push the boundaries of innovation and tackle some of the most pressing challenges facing gene editing development.
Both SOHM Inc. and Stanford University are renowned for their commitment to excellence and pushing the envelope in their respective domains. This partnership is set to amplify their impact and foster a culture of collaboration and creativity that will benefit not only the two entities involved but also the broader community.
"We are thrilled to embark on this collaborative journey with Stanford University on our ABBIE Technology," said David Aguilar, Ph. D COO. "By joining forces, we believe we can achieve far more together than we ever could alone. This partnership represents a merging of minds and resources that has the potential to drive significant positive change."
The details of specific projects and initiatives under this collaboration are expected to be unveiled in the coming months. Stay tuned for more updates on how SOHM, Inc. and Stanford University are shaping the future through their shared vision and collaboration.
For more information about SOHM Inc. and its work on ABBIE, please visit www.SOHM.com
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
What is the new collaboration announced by SOHM, Inc. (SHMN) on July 25, 2024?
What areas will the SOHM (SHMN) and Stanford University partnership focus on?
When will SOHM, Inc. (SHMN) reveal specific projects under the Stanford collaboration?
Who commented on the collaboration between SOHM (SHMN) and Stanford University?
